Hypercalcemia in post Stem Cell Transplant setting - A case report and review of literature
Abstract
Full Text:
PDFReferences
Stewart AF. Clinical practice. Hypercalcemia associated with cancer. The New England journal of medicine. 2005;352(4):373-9. Epub 2005/01/28.
Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanismsre- sponsible for osteolytic and osteoblastic metastasis to bone. Endocrine-related cancer. 2005;12(3): 549-83. Epub 2005/09/21.
Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289(5484):1504-8. Epub2000/09/01.
Martinez C, Polgreen LE, DeFor TE, Kivisto T, Petryk A, Tolar J, et al. Characterization andmanagement of hypercalcemia following transplantation for osteopetrosis. Bone marrow transplantation. 2010;45 (5):939-44. Epub 2009/10/06.
Lataillade JJ, Pierre-Louis O, Hasselbalch HC, Uzan G, Jasmin C, Martyre MC, et al. Doesprimary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood. 2008;112(8): 3026-35. Epub 2008/08/02.
Bock O, Loch G, Schade U, Busche G, Wasielewski R, Wiese B, et al. Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression ofosteoprotegerin. British journal of haematology. 2005;130 (1):76-82. Epub 2005/06/29.
Chagraoui H, Tulliez M, Smayra T, Komura E, Giraudier S, Yun T, et al. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood.2003;101(8):2983-9. Epub 2002/12/31.
Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, et al. Osteoprotegerinproduced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology. 2000;141(9):3478-84. Epub 2000/08/31.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
An initiative of The Tamil Nadu Dr M.G.R. Medical University